Last updated: June 8, 2026
Idvynso supplier landscape: who makes it, who supplies raw materials, and what to verify in bids
Idvynso is a branded pharmaceutical product, but supplier identification requires tying the brand to its active pharmaceutical ingredient (API), finished-dose manufacturer, and key excipient/packaging suppliers through FDA labeling (Current Good Manufacturing Practice), Orange Book, and procurement-grade supply chain disclosures. Those specifics are not provided here, so a complete, accurate supplier map cannot be produced from the available information.
What suppliers make Idvynso drug product (finished dose) and how do you identify them?
A finished-dose manufacturer is typically identified by:
- FDA labeling and prescribing information (manufactured for / distributed by language).
- NDC/labeler data and associated CGMP site listings.
- Orange Book entries for the listed products (manufacturer listed per NDA/labeler line).
- Inspectional history tied to the labeled site (if disclosed in public FDA records).
Which companies supply the Idvynso API and key starting materials?
API suppliers are typically identified by:
- Patent assignments and chemical synthesis disclosures in the Idvynso patent estate.
- DMF (Drug Master File) references for the NDA (when publicly indexed).
- Excipients and intermediates referenced in CMC sections and supplier qualification exhibits (rarely public).
- Regulatory submissions and inspection databases that connect the DMF-holder role.
How do you map Idvynso suppliers across US vs EU manufacturing sites?
Cross-region manufacturing mapping uses:
- Labeler/packager of record per region.
- NDA listing vs EMA product dossier manufacturing sites (if available).
- Sterile vs non-sterile controls and packaging lines.
- Quality agreements and QMS registration when publicly available.
What contract manufacturing organizations (CMOs) typically handle Idvynso dose forms?
Dose-form specific CMOs are identified by:
- Site-level GMP identity in FDA records for the labeled manufacturer.
- Public case studies, corporate disclosures, or investor decks naming the program.
- Launch-time procurement language in supplier capability announcements.
What Orange Book status and labeling details determine Idvynso supplier verification?
Supplier verification normally hinges on:
- Whether Idvynso is associated with an NDA and listed in the Orange Book.
- The listed drug entry that contains the applicant and manufacturer labeling.
- The presence of patent-linked manufacturing/formulation claims that often correlate with the CMC team and manufacturing site.
What bid-and-qualification checks should buyers run for Idvynso supply risk?
For a sourcing decision, buyers typically require:
- GMP compliance for the exact labeled site.
- Batch traceability from API through finished dose (CoA, CoC).
- Change control history for CMC, including site transfers.
- Supply continuity signals tied to capacity bookings and compendial controls.
Key Takeaways
No supplier list for Idvynso can be provided without the missing linkage between the brand and its NDA/labeler and API/CMO identifiers. A credible supplier map must be grounded in FDA labeling/Orange Book and CMC-linked manufacturing identities, none of which are included here.
FAQs
- How can I confirm the finished-dose manufacturer behind Idvynso from FDA sources?
- Where do I find Idvynso API manufacturer or DMF-holder identifiers?
- What documents show the real packaging and labeling supplier for Idvynso?
- How do Orange Book listings help validate Idvynso manufacturing sites?
- What supply-chain risks are most common when sourcing specialty branded pharmaceuticals like Idvynso?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA).
- U.S. Food and Drug Administration. Labeling and Prescribing Information database (accessed via Drug Labeling Repository). (FDA).
